August 2025 in “Dermatology and Therapy” This study conducted a meta-analysis of gene expression data from alopecia areata patients, identifying 5109 differentially expressed genes and highlighting enriched pathways like JAK-STAT signaling, providing insights into the disease's pathogenesis and potential treatment targets.
May 2025 in “Skin Appendage Disorders” This review reports that psoriatic alopecia, a type of hair loss linked to psoriasis, is difficult to diagnose and often resistant to conventional treatments, highlighting the need for further research into its immune-related mechanisms and personalized treatment approaches for better management.
July 2024 in “Journal of Investigative Dermatology” Sex and race affect immune responses and treatment outcomes in Hidradenitis suppurativa.
July 2024 in “Journal of Investigative Dermatology” Brepocitinib improves cicatricial alopecia and reduces key immune markers.
May 2024 in “International Journal of Molecular Sciences” This study found that injecting mouse hair follicle-derived mesenchymal stem cells (moMSCORS) into C57BL/6 mice reduced the incidence and severity of type 1 diabetes by modulating immune responses, suggesting potential for therapeutic use due to their immunosuppressive effects.
February 2024 in “Advanced Functional Materials” This study reported that a newly developed hydrogel patch, designed to recruit regulatory T cells through ROS-triggered release of CCL22, improved wound healing and hair follicle regeneration in a diabetic mouse model by scavenging ROS, thereby protecting Tregs and suppressing Th17 cells.
February 2024 in “Veterinary sciences” This study found that canine pemphigus foliaceus skin lesions exhibit a distinct immune signature, with upregulated pro-inflammatory and Th17-related genes, showing similarities to human pemphigus. Further research using advanced sequencing is needed to better understand the disease's pathogenesis.
January 2024 in “Biomedicines” This review discussed the cutaneous manifestations of APECED, highlighting chronic mucocutaneous candidiasis, alopecia areata, and vitiligo, while emphasizing the importance of early detection and monitoring for accurate diagnosis and patient care in various populations.
September 2023 in “Journal of the American Academy of Dermatology” Increased Treg cells and IL-10 may help quick recovery in acute diffuse and total alopecia.
June 2023 in “Research Square (Research Square)” This study identified shared gene expression changes and immune cell infiltration patterns that may contribute to hair loss in alopecia areata and cutaneous lupus erythematosus, but also highlighted factors that might preserve hair in psoriasis patients.
May 2023 in “Frontiers in Immunology” This article discusses the role of regulatory T cells in alopecia areata, where their deficiency in hair follicles may lead to impaired local immunity and suggests potential therapies like CAR-T reg cells and low-dose IL-2 to alleviate autoimmunity and promote hair regeneration in affected individuals.
April 2023 in “Journal of Investigative Dermatology” In this study, researchers developed a mouse model of scarring alopecia and observed significant reductions in CD200R expression in affected skin, potentially linking this signaling pathway to immune attacks on hair follicles and suggesting new treatment targets for scarring hair loss.
April 2023 in “Journal of Investigative Dermatology” This study found that mRNA booster vaccinations for SARS-CoV-2 increased protective antibodies without worsening autoimmune disease activity in patients with pemphigus and bullous pemphigoid.
April 2023 in “The journal of investigative dermatology/Journal of investigative dermatology” This study found that patients with alopecia areata had significantly lower frequencies of IL-10 producing CD19+CD24hiCD38hi regulatory B cells compared to healthy volunteers, suggesting a potential role for these cells in the autoimmune response seen in the condition.
January 2023 in “Discovery immunology” T cells and bacteria in the gut and skin help maintain health and protect against disease.
January 2023 in “Annals of dermatology/Annals of Dermatology” This study found that overexpression of miR-1246 in peripheral CD4+ T cells can reduce markers associated with inflammation and T cell activation in severe active alopecia areata, suggesting potential therapeutic benefits.
November 2022 in “The journal of investigative dermatology/Journal of investigative dermatology” This study found that skin organoids derived from iPSCs with an HS-associated NCSTN mutation showed defects in hair follicle stem cell differentiation and increased expression of inflammatory proteins related to hidradenitis suppurativa.
June 2022 in “Frontiers in Immunology” This report describes a case of alopecia universalis successfully treated with tofacitinib, though it was associated with increased peripheral blood cytokine levels.
March 2021 in “International Journal of Clinical Dermatology & Research” Dupilumab can help regrow hair in alopecia areata but stopping it may cause hair loss again.
December 2017 in “Annales de dermatologie et de vénéréologie” This article reviews key developments in pediatric dermatology for 2017, including consensus recommendations, novel genetic findings, and treatment insights for conditions like psoriasis and vascular malformations, without providing new clinical trial results.
April 2017 in “Journal of Investigative Dermatology” This study found that sulfated CCK octapeptide reduces psoriasis-like skin inflammation in mice, suggesting a new pathophysiological role for CCK in regulating epidermal inflammation.
August 2016 in “Journal of Investigative Dermatology” This quiz based on a Journal of Investigative Dermatology article reports no new clinical results but serves as an educational tool for diagnosing scalp conditions, including scalp psoriasis and psoriatic alopecia.
January 2015 in “프로그램북(구 초록집)” This study highlights that the combination of adapalene and benzoyl peroxide (Epiduo®) is an effective first-line treatment for acne, significantly inhibiting antibiotic-susceptible and antibiotic-resistant P. acnes strains.
January 2014 in “Journal of Jilin University” This study found that Th22 cells and their cytokine IL-22 may play an important role in the pathogenesis of systemic lupus erythematosus and could serve as bioindicators for monitoring disease severity.
January 2012 in “Journal of Investigative Dermatology” Small molecule DMF improves psoriasis and multiple sclerosis, adult skin cells can be made to grow new hair, certain skin cells initiate hair growth, IL-17C controls gut health and can cause skin inflammation, and skin cells produce IL-17 that can lead to psoriasis.
January 2025 in “Voprosy praktičeskoj pediatrii” This review found that autoimmune damage is a key factor in alopecia areata, noting its comorbidity with other diseases and the potential of Janus kinase inhibitors in treatment.
16 citations
,
October 2020 in “Lipids in Health and Disease” This review explores the current understanding of leptin's role in psoriasis and other skin diseases but reports no new clinical findings, emphasizing that the exact mechanisms of its impact are still being investigated.
1 citations
,
July 2025 in “Diagnostics” In this retrospective study, researchers found a statistically significant increase in the risk of alopecia areata among atopic dermatitis patients using dupilumab compared to controls, suggesting the need for careful monitoring and further research on the drug's impact on alopecia areata.
This study observed that patients using dupilumab for atopic dermatitis or chronic rhinosinusitis with nasal polyps may experience new-onset or worsening paradoxical alopecia areata, potentially due to unopposed Th1/Th17 immune activity following Th2 pathway blockade.
December 2025 in “Skin Health and Disease” This case report details the development of a psoriasiform rash and inflammatory alopecia in a 29-year-old man with severe atopic dermatitis following dupilumab treatment. The authors observed hair regrowth and eczema control after discontinuing dupilumab and beginning treatment with abrocitinib.